This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gennari, A. Articles by Conte, P. F. Search for Related Content PubMed PubMed Citation Articles by Gennari, A. Articles by Conte, P. F.

Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer

Alessandra Gennari, Dino Amadori, Mario De Lena, Oriana Nanni, Paolo Bruzzi, Vito Lorusso, Luigi Manzione, Pier Franco Conte

From the National Cancer Research Institute, Genoa; Morgagni-Pierantoni Hospital, Forli; Oncology Institute, Bari; Oncology Institute of Romagna; S. Carlo Hospital, Potenza; and the University of Modena and Reggio Emilia, Modena, Italy

Address reprint requests to Alessandra Gennari, MD, PhD, National Cancer Research Institute, Largo Rosanna Benzi, 10, 16132 Genoa, Italy; e-mail: alessandra.gennari{at}istge.it

PURPOSE: This randomized study compared maintenance paclitaxel with control in metastatic breast cancer patients not experiencing progression after first-line anthracycline/paclitaxel combination chemotherapy.

METHODS: Between April 1998 and October 2003, 459 metastatic breast cancer patients received first-line combination chemotherapy with epirubicin or doxorubicin plus paclitaxel. Of these, 255 who had a response or stable disease were then randomly assigned onto the Maintenance Paclitaxel 1 (MANTA1) study, comparing eight courses of maintenance paclitaxel versus control (ie, no additional chemotherapy administration). The primary end point was progression-free survival.

RESULTS: The study was prematurely concluded after a futility analysis, which was performed on 215 of the 238 patients randomly assigned within December 2002. Of these, 109 patients were assigned to maintenance paclitaxel and 106 were assigned to stopping chemotherapy. No significant difference in median progression-free survival was observed (8.0 months for maintenance paclitaxel and 9.0 months for control). There was no significant difference in median survival time (28.0 v 29.0 months). When the Bayesian method for monitoring clinical trials was applied to these data, even under an enthusiastic prior distribution, in the posterior distribution there was only an 8.6% chance of observing a 3-month improvement in median progression-free survival in the group receiving maintenance paclitaxel. After these results study accrual was closed.

CONCLUSION: Compared with control, the administration of additional courses of paclitaxel in patients who achieve disease control after six to eight courses of first-line anthracycline plus paclitaxel combination chemotherapy does not improve progression-free survival.

Supported in part by Associazione Italiana Ricerca sul Cancro (AIRC) and Bristol-Myers Squibb Italy.

Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. M. Llovet, A. M. Di Bisceglie, J. Bruix, B. S. Kramer, R. Lencioni, A. X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma J Natl Cancer Inst, May 21, 2008; 100(10): 698 - 711. [Abstract] [Full Text] [PDF]